Early preclinical results have demonstrated that the combination for checkpoint blockade inhibitors (CBI) could increase the tumor penetration of CD8+ T cells in order to improve the anti-tumor immune response alongside ADC cytotoxic killing of malignant cells. This evidence concerns the gene CD8A and neoplasm.